Bristol-Myers Squibb (BMS) has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz (atazanavir sulphate).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Bristol-Myers Squibb, Mylan, Reyataz, ANDA, US District Court for the District of New Jersey